Literature DB >> 24065443

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.

Jean G Diodati1, Jorge F Saucedo, John K French, Anthony Y Fung, Tracy E Cardillo, Carsten Henneges, Mark B Effron, Harold N Fisher, Dominick J Angiolillo.   

Abstract

BACKGROUND: Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clopidogrel may fail to provide adequate levels of platelet inhibition in patients with acute coronary syndrome undergoing percutaneous coronary intervention. METHODS AND
RESULTS: The pharmacodynamic response of prasugrel 60 mg ld alone was compared with prasugrel 60 mg or 30 mg added 24 hours to clopidogrel 600 mg in Transferring From Clopidogrel Loading Dose To Prasugrel Loading Dose In Acute Coronary Syndrome Patients study: a multicenter, randomized, double-blind, double-dummy, 3-arm, parallel, active-comparator controlled study. Two hundred eighty-two patients were randomized to 3 LD strategies: placebo plus prasugrel 60 mg, clopidogrel 600 mg plus prasugrel 60 mg, or clopidogrel 600 mg plus prasugrel 30 mg. Platelet function was assessed using VerifyNow P2Y12 Reaction Units (PRU) immediately before prasugrel LD, and 2, 6, 24, and 72 hours after prasugrel LD in 149 patients with evaluable platelet function studies. At 6 hours after the prasugrel 60 mg LD, the least squares mean (95% confidence interval) difference between placebo/prasugrel 60 mg and clopidogrel 600 mg/prasugrel 60 mg (primary outcome) was 22.2 (-11.0 to 55.5; P=0.19; least squares mean PRU 57.9 versus 35.6, respectively). For clopidogrel 600 mg/prasugrel 30 mg (least squares mean PRU, 53.9), the difference was 3.9 (-28.2 to 36.1; P=0.81) versus placebo/prasugrel 60 mg. No significant differences in PRU were observed at any time point across the 3 groups. There were few bleeding events observed regardless of treatment.
CONCLUSIONS: Platelet reactivity with prasugrel 60 mg LD added to clopidogrel 600 mg LD was not significantly different compared with prasugrel 60 mg LD alone in acute coronary syndrome patients undergoing percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01115738.

Entities:  

Keywords:  acute coronary syndrome; clopidogrel; platelet function tests; prasugrel

Mesh:

Substances:

Year:  2013        PMID: 24065443     DOI: 10.1161/CIRCINTERVENTIONS.112.000063

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  6 in total

Review 1.  Switching P2Y12-receptor inhibitors in patients with coronary artery disease.

Authors:  Fabiana Rollini; Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2015-08-18       Impact factor: 32.419

2.  Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.

Authors:  Manuel Almendro-Delia; Emilia Blanco Ponce; Rocío Gomez-Domínguez; Carlos Gonzalez-Matos; Manuel Lobo-Gonzalez; Auxiliadora Caballero-Garcia; Rafael Hidalgo-Urbano; Maria Jose Cruz-Fernandez; Juan C Garcia-Rubira
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

Review 3.  Novel antiplatelet agents in acute coronary syndrome.

Authors:  Francesco Franchi; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2014-10-07       Impact factor: 32.419

4.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

5.  Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic review and meta-analysis including 22,500 patients from 14 studies.

Authors:  Enrico Cerrato; Matteo Bianco; Akshay Bagai; Leonardo De Luca; Simone Biscaglia; Alessia Luciano; Paola Destefanis; Giorgio Quadri; Ilaria Meynet; Carol Gravinese; Alessandra Chinaglia; Shaun G Goodman; Roberto Pozzi; Gianluca Campo; Ferdinando Varbella
Journal:  Int J Cardiol Heart Vasc       Date:  2018-12-08

6.  Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.

Authors:  Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh
Journal:  CJC Open       Date:  2020-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.